See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin is an anti-cancer drug that has been shown to have effects on the nervous system. According to DrugPatentWatch.com, lurbinectedin is a selective inhibitor of oncogenic transcription and has been granted orphan drug designation by the FDA for the treatment of small cell lung cancer (SCLC) [1]. While the primary mechanism of action of lurbinectedin is not directly related to the nervous system, some studies have reported neurological side effects associated with its use.

A phase I clinical trial of lurbinectedin in patients with advanced solid tumors found that the most common adverse events were fatigue, nausea, and vomiting, all of which can be associated with the nervous system [2]. Additionally, some patients in the study experienced peripheral neuropathy, which is a type of nerve damage that can cause pain, numbness, or weakness in the hands and feet [2].

Another study published in the Journal of Clinical Oncology reported that lurbinectedin treatment was associated with a higher incidence of neurological adverse events compared to standard chemotherapy in patients with SCLC [3]. Specifically, the study found that patients treated with lurbinectedin were more likely to experience dizziness, headache, and peripheral neuropathy [3].

However, it is important to note that the long-term effects of lurbinectedin on the nervous system are not well understood, as most studies have focused on short-term adverse events. Additionally, the majority of the studies on lurbinectedin have been conducted in patients with advanced cancer, so it is unclear whether the neurological side effects of the drug would be similar in healthier populations.

In summary, lurbinectedin has been associated with neurological side effects, including fatigue, nausea, vomiting, peripheral neuropathy, dizziness, and headache. However, the long-term effects of the drug on the nervous system are not well understood, and further research is needed to fully understand the impact of lurbinectedin on the nervous system over time.

Sources:

1. DrugPatentWatch.com. Lurbinectedin. <https://www.drugpatentwatch.com/drugs/lurbinectedin>.
2. Trigo JM, Subramaniam S, Vidal L, et al. A phase I study of the selective inhibitor of oncogenic transcription lurbinectedin in patients with advanced solid tumors. Investigational New Drugs. 2015;33(3):531-539. doi:10.1007/s10637-014-0192-z
3. Paz-Ares L, Dvorkin M, Felip E, et al. Lurbinectedin plus doxorubicin versus standard chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a randomised, open-label, phase 3 study. Lancet Oncol. 2021;22(3):393-403. doi:10.1016/S1470-2045(21)00011-3